Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

A Coefficient of Agreement for Nominal Scales

Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398

Statistical Methods for Rates and Proportions

Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005

Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S.

Toutenburg, H. (1974) · Biometrische Zeitschrift · doi:10.1002/bimj.19740160814 · Cited by 1,547

The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study

Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., Franzini, L., Williams, A., de Haes, H. C., Hopwood, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2756 · Cited by 1,220

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906

Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study

Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30

Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.025 · Cited by 555

Physicians' and patients' choices in evidence based practice

Haynes, R. B., Devereaux, P. J., & Guyatt, G. H. (2002) · BMJ · doi:10.1136/bmj.324.7350.1350 · Cited by 534

Correlation of patient and caregiver ratings of cancer pain

Grossman, S. A., Sheidler, V. R., Swedeen, K., Mucenski, J. W., & Piantadosi, S. (1991) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(91)90518-9 · Cited by 434

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Dueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., Atkinson, T. M., Bennett, A. V., Denicoff, A. M., O'Mara, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2639 · Cited by 1,030

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

de Boer, S. M., Powell, M. E. B., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Méder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30079-2 · Cited by 646

Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study

Pearce, A. M., Haas, M. R., Viney, R. C., Pearson, S., Haywood, P., Brown, C. S. B., & Ward, R. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184360 · Cited by 542

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline

Di Maio, M., Basch, E., Denis, F., Fallowfield, L. J., Ganz, P. A., Howell, D., Kowalski, C., Perrone, F., Stover, A. M., Sundaresan, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.007 · Cited by 509

Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting

Navari, R. M., & Aapro, M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515442 · Cited by 479

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial

Basch, E., Schrag, D., Henson, S., Jansen, J., Ginos, B., Stover, A. M., Carr, P., Spears, P. A., Jonsson, M., Deal, A. M., et al. (2022) · JAMA · doi:10.1001/jama.2022.9265 · Cited by 413

The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review

Atkinson, T. M., Ryan, S. J., Bennett, A. V., Stover, A. M., Saracino, R. M., Rogak, L. J., Jewell, S., Matsoukas, K., Li, Y., & Basch, E. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3297-9 · Cited by 371

A review of the barriers to using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine cancer care

Nguyen, H., Butow, P., Dhillon, H., & Sundaresan, P. (2021) · Journal of Medical Radiation Sciences · doi:10.1002/jmrs.421 · Cited by 351

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

Maïo, M. D., Basch, E., Bryce, J., & Perrone, F. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.222 · Cited by 261

The increasing value of eHealth in the delivery of patient-centred cancer care

Penedo, F. J., Oswald, L. B., Kronenfeld, J. P., Garcia, S. F., Cella, D., & Yanez, B. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30021-8 · Cited by 252

The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events

Kawaguchi, T., Azuma, K., Sano, M., Kim, S., Kawahara, Y., Sano, Y., Shimodaira, T., Ishibashi, K., Miyaji, T., Basch, E., et al. (2018) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-017-0022-5 · Cited by 248

The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real-World”: Results from the Population-Based PROFILES Registry

Husson, O., de Rooij, B. H., Kieffer, J. M., Oerlemans, S., Mols, F., Aaronson, N. K., van der Graaf, W. T. A., & van de Poll-Franse, L. V. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0348 · Cited by 251

Patient-reported outcomes in cancer care — hearing the patient voice at greater volume

LeBlanc, T. W., & Abernethy, A. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.153 · Cited by 254

A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer

Ong, W. L., Schouwenburg, M. G., van Bommel, A. C. M., Stowell, C. J., Allison, K. H., Benn, K., Browne, J. P., Cooter, R. D., Delaney, G. P., Duhoux, F. P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4851 · Cited by 246

Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis

Blanchard, P., Garden, A. S., Gunn, G. B., Rosenthal, D. I., Morrison, W. H., Hernández, M., Crutison, J., Lee, J. J., Ye, R., Fuller, C. D., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.05.022 · Cited by 230

Challenges, solutions and future directions in the evaluation of service innovations in health care and public health

Raine, R., Fitzpatrick, R. M., Barratt, H., Bevan, G., Black, N. A., Boaden, R., Bower, P., Campbell, M., Denis, J., Devers, K. J., et al. (2016) · Health Services and Delivery Research · doi:10.3310/hsdr04160 · Cited by 197

Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus

Lambrecht, M. L. F., Eekers, D. B. P., Alapetite, C., Burnet, N. G., Calugaru, V., Coremans, I. E. M., Fossati, P., Høyer, M., Langendijk, J. A., Romero, A. M., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.001 · Cited by 188

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

de Boer, S. M., Powell, M. E. B., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Méder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30120-6 · Cited by 177

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer

Ding, P. N., Lord, S. J., Gebski, V., Links, M. J., Bray, V., Gralla, R. J., Yang, J. C., & Lee, C. K. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2236 · Cited by 174

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Pignata, S., Lorusso, D., Scambia, G., Sambataro, D., Tamberi, S., Cinieri, S., Mosconi, A. M., Orditura, M., Brandes, A. A., Arcangeli, V., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70115-4 · Cited by 163

Time to Stop Saying Geriatric Assessment Is Too Time Consuming

Hamaker, M. E., Wildes, T. M., & Rostoft, S. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8170 · Cited by 159

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

Rose, T. L., Harrison, M. R., Deal, A. M., Ramalingam, S., Whang, Y. E., Brower, B., Dunn, M. W., Osterman, C. K., Heiling, H., Bjurlin, M. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01003 · Cited by 145

Innovations in research and clinical care using patient‐generated health data

Jim, H., Hoogland, A. I., Brownstein, N. C., Barata, A., Dicker, A. P., Knoop, H., Gonzalez, B. D., Perkins, R. M., Rollison, D. E. M., Gilbert, S. M., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21608 · Cited by 149

CINV: still troubling patients after all these years

Aapro, M. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4131-3 · Cited by 127

Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial

de Boer, S. M., Nout, R. A., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Mens, J. W., Slot, A., Kroese, M. C. S., Oerlemans, S., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.08.023 · Cited by 123

Relevance of randomised controlled trials in oncology

Tannock, I. F., Amir, E., Booth, C. M., Niraula, S., Ocaña, A., Šeruga, B., Templeton, A. J., & Vera-Badillo, F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30572-1 · Cited by 121

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Martínez-Lage, M., Torres-Ruiz, R., Puig-Serra, P., Moreno-Gaona, P., Martín, M. C., Moya, F., Bustamante, O. Q., Garcı́a-Silva, S., Carcaboso, A. M., Petazzi, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18875-x · Cited by 118

Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial

Dai, W., Feng, W., Zhang, Y., Wang, X. S., Liu, Y., Pompili, C., Xu, W., Xie, S.-H., Wang, Y., Liao, J. X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01344 · Cited by 120

Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254

Thanarajasingam, G., Atherton, P. J., Novotny, P. J., Loprinzi, C. L., Sloan, J. A., & Grothey, A. A. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00038-3 · Cited by 116

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

Terpos, E., Mikhael, J. R., Hájek, R., Chari, A., Zweegman, S., Lee, H. C., Mateos, M., Larocca, A., Ramasamy, K., Kaiser, M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00432-4 · Cited by 116

Under-reporting of harm in clinical trials

Šeruga, B., Templeton, A. J., Badillo, F. E. V., Ocaña, A., Amir, E., & Tannock, I. F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00152-2 · Cited by 110

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

Marandino, L., Salvia, A. L., Sonetto, C., Luca, E. D., Pignataro, D., Zichi, C., Stefano, R. F. D., Ghisoni, E., Lombardi, P., Mariniello, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy449 · Cited by 104

Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials

Basch, E., Rogak, L. J., & Dueck, A. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.011 · Cited by 101

Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study

Jensen, N. B. K., Pötter, R., Kirchheiner, K., Fokdal, L. U., Lindegaard, J. C., Kirisits, C., Mazeron, R., Mahantshetty, U. M., Jurgenliemk-Schulz, I. M., Šegedin, B., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.016 · Cited by 98

Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia

Lam, M. S., & Cheung, N. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215608523 · Cited by 95

Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology

Warsame, R. M., & D’Souza, A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.04.005 · Cited by 95

Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?

Efficace, F., Gaïdano, G., & Lo‐Coco, F. (2017) · Blood · doi:10.1182/blood-2017-03-737403 · Cited by 94

Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey

party, O. B. O. T. I. F. D. W., McCrary, J. M., Goldstein, D., Boyle, F. M., Cox, K., Grimison, P., Kiernan, M. C., Krishnan, A. V., Lewis, C. R., Webber, K., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3772-y · Cited by 93

The HOPE Pilot Study: Harnessing Patient-Reported Outcomes and Biometric Data to Enhance Cancer Care

Wright, A. A., Raman, N., Staples, P. C., Schonholz, S. M., Cronin, A. M., Carlson, K. W., Keating, N. L., & Onnela, J.-P. “. (2018) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00149 · Cited by 94

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial

Basch, E., Schrag, D., Jansen, J., Henson, S. R., Ginos, B., Stover, A. M., Carr, P. M., Spears, P. A., Jönsson, M., Deal, A. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03507-y · Cited by 94

The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials

Thanarajasingam, G., Hubbard, J. M., Sloan, J. A., & Grothey, A. F. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv216 · Cited by 88

Electronic Patient-Reported Outcomes: The Time Is Ripe for Integration Into Patient Care and Clinical Research

Schwartzberg, L. S. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158749 · Cited by 83

Treatment of refractory thyroid cancer

Berdelou, A., Lamartina, L., Klain, M., Leboulleux, S., Schlumberger, M. J., & _, _. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0542 · Cited by 86

Response by Ward et al to Letter Regarding Article, “Statin Toxicity: Mechanistic Insights and Clinical Implications”

Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.119.315233 · Cited by 84

Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis

Caputo, R., Buono, G., Piezzo, M., Martinelli, C., Cianniello, D., Rizzo, A., Pantano, F., Staropoli, N., Cangiano, R., Turano, S., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1362641 · Cited by 78

A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures

Oosten, A. W., Oldenmenger, W. H., Mathijssen, R. H. J., & van der Rijt, C. C. D. (2015) · Journal of Pain · doi:10.1016/j.jpain.2015.05.006 · Cited by 74

Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer

Montemurro, F., Mittica, G., Cagnazzo, C., Longo, V., Berchialla, P., Solinas, G., Culotta, P., Martinello, R., Foresto, M., Gallizioli, S., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4720 · Cited by 74

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial

Khalaf, D. J., Sunderland, K., Eigl, B. J., Kollmannsberger, C., Ivanov, N., Finch, D. L., Oja, C. D., Vergidis, J., Zulfiqar, M., Gleave, M. E., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.12.015 · Cited by 75

Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer

Nipp, R. D., El-Jawahri, A. R., Ruddy, M., Fuh, C., Temel, B., D’Arpino, S., Cashavelly, B. J., Jackson, V. A., Ryan, D. P., Hochberg, E. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy488 · Cited by 71

A specific method for qualitative medical research: the IPSE (Inductive Process to analyze the Structure of lived Experience) approach

Sibéoni, J., Verneuil, L., Manolios, É., & Révah‐Levy, A. (2020) · BMC Medical Research Methodology · doi:10.1186/s12874-020-01099-4 · Cited by 87

Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial

Tran, C. N., Dicker, A. P., Leiby, B. E., Gressen, E. L., Williams, N. L., & Jim, H. (2019) · Journal of Medical Internet Research · doi:10.2196/12689 · Cited by 66

The Incidence and Severity of Patient-Reported Side Effects of Chemotherapy in Routine Clinical Care: A Prospective Observational Study

Katta, B., Vijayakumar, C., Dutta, S., Dubashi, B., & Ramakrishnaiah, V. P. N. (2023) · Cureus · doi:10.7759/cureus.38301 · Cited by 68

Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data

Aapro, M., Scotté, F., Escobar, Y., Celio, L., Berman, R. B., Franceschetti, A., Bell, D., & Jordan, K. (2021) · The Oncologist · doi:10.1002/onco.13716 · Cited by 66

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

Cortés, J., Hudgens, S. A., Twelves, C., Perez, E. A., Awada, A. H., Yelle, L., McCutcheon, S., Kaufman, P. A., Forsythe, A., & Velikova, G. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3633-7 · Cited by 65

Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice

Beijers, A. J. M., Vreugdenhil, G., Oerlemans, S., Eurelings, M., Minnema, M. C., Eeltink, C., van de Poll-Franse, L. V., & Mols, F. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-3032-y · Cited by 67

Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant

Sidana, S., Dueck, A. C., Thanarajasingam, G., Griffin, J. M., Thompson, C. A., Durani, U., Burtis, M., Warsame, R. M., Paludo, J., Gertz, M. A., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.004 · Cited by 66

Improving cancer immunotherapy by targeting the STATe of MDSCs

de Haas, N., de Koning, C. C. H., Spilgies, L. M., de Vries, I. J. M., & Hato, S. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196312 · Cited by 63

Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients

Bæksted, C., Pappot, H., Nissen, A., Hjøllund, N. H., Mitchell, S. A., Basch, E., Bidstrup, P. E., Dalton, S. O., & Johansen, C. (2017) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-017-0005-6 · Cited by 60

Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials

Veitch, Z. W. N., Shepshelovich, D., Gallagher, C., Wang, L. E., Razak, A. R. A., Spreafico, A., Bedard, P. L., Siu, L. L., Minasian, L. M., & Hansen, A. R. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab015 · Cited by 60

Hormonal treatment and quality of life of prostate cancer patients: new evidence

Tucci, M., Leone, G., Buttigliero, C., Zichi, C., Stefano, R. F. D., Pignataro, D., Vignani, F., Scagliotti, G. V., & Maïo, M. D. (2018) · Minerva Urology and Nephrology · doi:10.23736/s0393-2249.17.03066-1 · Cited by 57

Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care—A Systematic Review

Hall, E. T., Singhal, S., Dickerson, J. C., Gabster, B. P., Wong, H.-N., Aslakson, R. A., Schapira, L., Aslakson, R. A., Ast, K., Carroll, T., et al. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.03.015 · Cited by 54

Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

Rammant, E., Ost, P., Swimberghe, M., Vanderstraeten, B., Lumen, N., Decaestecker, K., Bultijnck, R., Meerleer, G. D., Sarrazyn, C., Colman, R., et al. (2018) · Strahlentherapie und Onkologie · doi:10.1007/s00066-018-1395-y · Cited by 55

Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade

Tan, A. C., McCrary, J. M., Park, S. B., Trinh, T., & Goldstein, D. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04781-6 · Cited by 55

Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification

Trapani, D., Franzoi, M. A., Burstein, H. J., Carey, L., Delaloge, S., Harbeck, N., Hayes, D. F., Kalinsky, K. M., Pusztai, L., Regan, M. M., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.03.273 · Cited by 54

A Practical Approach to Fatigue Management in Colorectal Cancer

Aapro, M., Scotte, F., Bouillet, T., Currow, D., & Vigano, A. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.04.010 · Cited by 54

Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population

Mols, F., van de Poll-Franse, L. V., Vreugdenhil, G., Beijers, A. J. M., Kieffer, J. M., Aaronson, N. K., & Husson, O. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.020 · Cited by 54

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists

Bosnjak, S. M., Gralla, R. J., & Schwartzberg, L. S. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3585-z · Cited by 55

Using patient‐reported outcomes (PROs) and patient‐reported outcome measures (PROMs) in routine head and neck cancer care: What do health professionals perceive as barriers and facilitators?

Nguyen, H., Butow, P. N., Dhillon, H. M., Morris, L. M., Brown, A. H., West, K., & Sundaresan, P. (2020) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13048 · Cited by 53

The Effects of Patient-Reported Outcome Screening on the Survival of People with Cancer: A Systematic Review and Meta-Analysis

Caminiti, C., Maglietta, G., Diodati, F., Puntoni, M., Marcomini, B., Lazzarelli, S., Pinto, C., & Perrone, F. (2022) · Cancers · doi:10.3390/cancers14215470 · Cited by 53

Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam

Nguyen, S. M., Pham, A. T., Nguyen, L. M., Cai, H., Tran, T. V., Shu, X., & Tran, H. T.-T. (2022) · Current Oncology · doi:10.3390/curroncol29110653 · Cited by 52

Including the patient voice in the development and implementation of patient‐reported outcomes in cancer clinical trials

Addario, B. J., Geißler, J., Horn, M. K., Krebs, L. U., Maskens, D. A., Oliver, K. R., Plate, A., Schwartz, E. C., & Willmarth, N. E. (2019) · Health Expectations · doi:10.1111/hex.12997 · Cited by 52

Electronic real-time assessment of patient-reported outcomes in routine care—first findings and experiences from the implementation in a comprehensive cancer center

Trautmann, F., Hentschel, L., Hornemann, B., Rentsch, A., Baumann, M. A., Ehninger, G., Schmitt, J. M., & Schuler, M. K. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3127-0 · Cited by 51

Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care?

Husson, O., Younger, E., Dunlop, A., Dean, L., Strauß, D., Benson, C., Hayes, A. J., Miah, A. B., van Houdt, W. J., Zaidi, S., et al. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4386-8 · Cited by 50

Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium

Franzoi, M. A., Ferreira, A. R., Lemaire, A., Rodriguez, J., Grosjean, J., Ribeiro, J. M., Polastro, L., Grellety, T., Artignan, X., Le Du, K., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101005 · Cited by 50

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

Post, C., de Boer, S. M., Powell, M. E. B., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Méder, C., Ottevanger, N. P. B., Ledermann, J. A., Khaw, P., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.10.030 · Cited by 48

Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Bæksted, C., Nissen, A., Pappot, H., Bidstrup, P. E., Mitchell, S. A., Basch, E., Dalton, S. O., & Johansen, C. (2016) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2016.02.008 · Cited by 46

Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

Galizia, D., Milani, A., Geuna, E., Martinello, R., Cagnazzo, C., Foresto, M., Longo, V., Berchialla, P., Solinas, G., Calori, A., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1687 · Cited by 47

Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment

Jacobsen, P. B., Nipp, R. D., & Ganz, P. A. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175673 · Cited by 48

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Harbeck, N., Fasching, P. A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R. E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.003 · Cited by 48

Treatment‐related toxicities of immune checkpoint inhibitors in advanced cancers: A meta‐analysis

Man, J., Ritchie, G. E., Links, M. J., Lord, S. J., & Lee, C. K. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12838 · Cited by 46

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study

Botticelli, A., Caputo, R., Scagnoli, S., Pisegna, S., Laurentiis, M. D., Curigliano, G., Lambertini, M., Pantano, F., Palazzo, A., Paris, I., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad308 · Cited by 46

Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables

Chandwani, K. D., Zhao, F., Morrow, G. R., Deshields, T. L., Minasian, L. M., Manola, J. B., & Fisch, M. J. (2017) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2016.12.347 · Cited by 44

Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study

Ohashi, T., Yorozu, A., Saito, S., Tanaka, N., Katayama, N., Kojima, S., Maruo, S., Kikuchi, T., Dokiya, T., Fukushima, M., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.05.014 · Cited by 43

Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours

Dutz, A., Lühr, A., Agolli, L., Troost, E. G. C., Krause, M., Baumann, M. A., Vermeren, X., Geismar, D., Lebow, E. S., Bussiere, M. R., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.06.036 · Cited by 43

Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients’ and Clinicians’ Experiences

Tolstrup, L. K., Pappot, H., Bastholt, L., Zwisler, A., & Dieperink, K. B. (2020) · Journal of Medical Internet Research · doi:10.2196/14896 · Cited by 43

Missing Patients’ Symptoms in Cancer Care Delivery—The Importance of Patient-Reported Outcomes

Basch, E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4719 · Cited by 43

Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Balhara, Y. P. S., Sarkar, S., & Gupta, R. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.159023 · Cited by 42

Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance

Fornasier, G., Taborelli, M., Francescon, S., Polesel, J., Aliberti, M., Paoli, P. D., & Baldo, P. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0653-5 · Cited by 41

Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff

Kennedy, F., Shearsmith, L., Ayres, M., Lindner, O. C., Marston, L., Pass, A., Danson, S. J., & Velikova, G. (2020) · Clinical Trials · doi:10.1177/1740774520972125 · Cited by 39

Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials

Holch, P., Henry, A. M., Davidson, S. E., Gilbert, A., Routledge, J. A., Shearsmith, L., Franks, K., Ingleson, E., Albutt, A., & Velikova, G. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.11.008 · Cited by 39

Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials

Trask, P. C., Dueck, A. C., Piault, E. C., & Campbell, A. (2018) · Clinical Trials · doi:10.1177/1740774518799985 · Cited by 39

Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer

Mougalian, S. S., Epstein, L. N., Jhaveri, A. P., Han, G., Abu-Khalaf, M. M., Hofstatter, E. W., DiGiovanna, M. P., Silber, A. L. M., Adelson, K. B., Pusztai, L., et al. (2017) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00015 · Cited by 42

Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review

Safa, H., Tamil, M. K., Spiess, P. E., Manley, B. J., Pow‐Sang, J. M., Gilbert, S. M., Safa, F. M., Gonzalez, B. D., Oswald, L. B., Semaan, A., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa174 · Cited by 37

Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health

Banerjee, R. K., Shah, N. D., & Dicker, A. P. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.21.00023 · Cited by 38

Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer

Nipp, R. D., Horick, N., Qian, C. L., Knight, H. P., Kaslow-Zieve, E. R., Azoba, C. C., Elyze, M., Landay, S. L., Kay, P. S., Ryan, D. P., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.7643 · Cited by 38

Symptom documentation and intervention provision for symptom control in children receiving cancer treatments

Hyslop, S., Davis, H., Duong, N., Loves, R. H., Schechter, T., Tomlinson, D., TOMLINSON, G. A., Dupuis, L. L., & Sung, L. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.002 · Cited by 36

Better understanding the downsides of low value healthcare could reduce harm

Brownlee, S., & Korenstein, D. R. (2021) · BMJ · doi:10.1136/bmj.n117 · Cited by 34

Patient‐reported symptom burden in routine oncology care: Examining racial and ethnic disparities

Bulls, H. W., Chang, P., Brownstein, N. C., Zhou, J., Hoogland, A. I., Gonzalez, B. D., Johnstone, P. A. S., & Jim, H. (2021) · Cancer Reports · doi:10.1002/cnr2.1478 · Cited by 34

Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov

Lai-Kwon, J. E., Yin, Z., Minchom, A. R., & Yap, C. (2021) · Cancer Medicine · doi:10.1002/cam4.4307 · Cited by 32

A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams

Stenson, C. L., Vidrine, J., Dewhurst, F., Osborne, W., Menne, T., & Stocker, R. (2023) · Palliative Medicine · doi:10.1177/02692163221138880 · Cited by 34

Symptomatic Toxicities Experienced During Anti-Cancer Treatment: Comparison of Patients' and Physicians' Reporting in Three Randomized Controlled Trials (Rcts)

Maïo, M. D., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., Placido, S. D., Ceribelli, A., Favaretto, A. G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu356.2 · Cited by 1

Doctors less likely than patients to report toxicity of cancer treatments, study shows

Mayor, S. (2015) · BMJ · doi:10.1136/bmj.h485 · Cited by 1

Under-reporting of subjective symptoms and its prognostic value. A pooled analysis of 12 cancer clinical trials.

Arenare, L., Liello, R. D., Placido, P. D., Gridelli, C., Morabito, A., Pignata, S., Nuzzo, F., Avallone, A., Maiello, E., Gargiulo, P., et al. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8309691

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)

Gravis, G., Marino, P., Joly, F., Oudard, S. M., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.034 · Cited by 69

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

Perrone, F., Basch, E., Bryce, J., & Maïo, M. D. (2022) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/sc1k-1404